Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2
Mark C. de Gooijer(Manchester Academic Health Science Centre), Olaf van Tellingen(The Netherlands Cancer Institute), Tessa Buckle(Leiden University Medical Center), Willem Boogerd(The Netherlands Cancer Institute), Nienke A. de Vries(The Netherlands Cancer Institute), Levi C.M. Buil(Cancer Genomics Centre), Jos H. Beijnen(The Netherlands Cancer Institute)
Cited by 137
Related Papers
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose Chemotherapy
|JNCI Journal of the National Cancer Institute|1998|768
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
|PubMed|2002|507
Clinical Pharmacokinetics of Cyclophosphamide
|Clinical Pharmacokinetics|2005|451